RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Cannaccord 42ndI agree that Paul's tone was positive, but there is a big hole in Thera's story, and it's about confirmation of sortilin overexpression. Remember that they explained the requirement by FDA to enroll all comers in the phase Ia saying that FDA wanted to see if any efficacy would correlate with sortilin overexpression. That was reason to enroll all comers. If patients not overexpressing sortilin would show efficacy, it would be problematic because the whole thing is based on sortilin overexpression. For the FDA to make that assessment, Thera needs to provide them with sortilin expression data on tumors. Maybe they did, but they disclosed nothing about that.
The other thing linked to sortilin expression level is toxicity. If a patient has no sortilin overexpression on his tumors, toxicity level should be higher because les TH1902 goes into cells. That leads to the other strange thing, Levesque reiterataed today that they saw low level of free docetaxel in the bloodstream, but with all comers in phase Ia, level of free docetaxel should vary between patients with no sortilin overexpression and those with high overexpression, also, add tumor burden in the mix. Also, in the July 14 press release, the company talks about low level of free docetaxel, but does not give any specifics. Free docetaxel concentration will be much lower with TH1902 anyways because it acts as a slow release mechanism. The key is not the concentration at a given point after injection, it's the area under the curve (AUC) established by multiple testing points. So the way they phrase it in the press release is not specific. Again, the AUC between a patient with high sortilin expression and a patient with low sortilin expression cannot be similar. If the concept works, there should be significant differences, at least with patients with relatively high tumor burden.
Again, the free docetaxel curve of TH1902 will be very different from the curve of free docetaxel injected alone. The Cmax will be much higher for free docetaxel injected alone, since TH1902 acts as as slow release system. So the whole sortilin part of the PDC concept equation is unknown at this point. They gave no data to prove the role of sortilin overexpression in the whole thing. Efficacy signs lead to think the concept works, in initially I was affirmative about that, but the more I hear them providing no data to corroborate that, the more I doubt. I don't say the concept is not working. All I say is that they provided no data about the role of sortilin.
SPCEO1 wrote: The most obvious reason to own TH's stock is largely because of the IMMU potential is has. If it turns out it is even 20% of what IMMU was, it is a very big deal for longs. It is nice to also have a fall back position in the legacy drugs and I have to think every investor, other than possibly someone who is short the stock, which is virtually no one at this point perhaps with the exception of you, would be happy for the sales of the legacy drugs to get reinvigorated.
If you are short, and no one who posts the stuff you post could possibly be both long and sane, I can see why Paul's confident presentation today regarding "a few, several, maybe many" responders in cancer by Christmas might freak you out and cause your eruption of FUD posts. But if you are sane, you also know your negative diatribes here are not convincing any of the many really sound long term investors who frequent this board. So what's is the point of your antics?
Trogarzon wrote:
if you dont come out of this with a good reason to buy the stock or having a better sense of where you are and where you are going what have you achieved. Talking about the sales force and adding products is a plan b proposition and one that I dont like since its a distraction and a diversion from th1902.. thats what I smell here